Metabolisme af efalizumab bliver efter systemisk fordeling fulgt af intracellulær nedbrydning som følge af binding til enten celleoverflade CD11a eller via endocytose.
The metabolism of efalizumab is through internalisation followed by intracellular degradation as a consequence of either binding to cell surface CD11a or through endocytosis.